[go: up one dir, main page]

ATE521624T1 - Peptide und medizinische zusammensetzungen mit denselben - Google Patents

Peptide und medizinische zusammensetzungen mit denselben

Info

Publication number
ATE521624T1
ATE521624T1 AT03775859T AT03775859T ATE521624T1 AT E521624 T1 ATE521624 T1 AT E521624T1 AT 03775859 T AT03775859 T AT 03775859T AT 03775859 T AT03775859 T AT 03775859T AT E521624 T1 ATE521624 T1 AT E521624T1
Authority
AT
Austria
Prior art keywords
peptides
pacap
same
provides
medicinal compositions
Prior art date
Application number
AT03775859T
Other languages
English (en)
Inventor
Satomi Onoue
Kousuke Endo
Asami Matsumoto
Original Assignee
Ils Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ils Inc filed Critical Ils Inc
Application granted granted Critical
Publication of ATE521624T1 publication Critical patent/ATE521624T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
AT03775859T 2002-11-27 2003-11-21 Peptide und medizinische zusammensetzungen mit denselben ATE521624T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002344523 2002-11-27
PCT/JP2003/014924 WO2004048401A1 (ja) 2002-11-27 2003-11-21 ペプチド及びこれを含む医薬組成物

Publications (1)

Publication Number Publication Date
ATE521624T1 true ATE521624T1 (de) 2011-09-15

Family

ID=32375955

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03775859T ATE521624T1 (de) 2002-11-27 2003-11-21 Peptide und medizinische zusammensetzungen mit denselben

Country Status (10)

Country Link
US (1) US7332473B2 (de)
EP (1) EP1571155B1 (de)
JP (1) JP4477506B2 (de)
KR (1) KR20050067439A (de)
CN (1) CN100381462C (de)
AT (1) ATE521624T1 (de)
AU (1) AU2003284428B2 (de)
CA (1) CA2507616A1 (de)
ES (1) ES2368565T3 (de)
WO (1) WO2004048401A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997381B (zh) * 2004-04-23 2011-06-08 千寿制药株式会社 含有pacap及其衍生物的角膜神经突形成促进剂
JP2008537542A (ja) * 2005-03-07 2008-09-18 モンドビーオテッヒ ライセンシング オアト アーゲー アビプタジルのための処方物
KR20080082597A (ko) * 2005-07-28 2008-09-11 글로벌 리서치 테크놀로지스, 엘엘씨 공기로부터 이산화탄소의 제거
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
JP2009525946A (ja) 2005-12-20 2009-07-16 デューク・ユニヴァーシティ 増強された薬理学的性質を有する活性物質を送達するための方法および組成物
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
AU2007241809A1 (en) 2006-04-20 2007-11-01 Itoham Foods Inc. Pharmaceutical composition for conformational disease
EP2187901B1 (de) * 2007-09-11 2012-08-08 Mondobiotech Laboratories AG Neuropeptid El und optional ACTH (7-38) zur Verwendung in der antiangiogenen Therapie
CN105727261A (zh) 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
NZ592612A (en) * 2008-10-17 2013-01-25 Vectus Biosystems Pty Ltd Vasoactive intestinal peptide (VIP) Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-X for the treatment of kidney disorders
KR101943420B1 (ko) 2009-08-14 2019-04-17 파세비오 파마수티컬스 인코포레이티드 변형된 혈관활성 장 펩티드
WO2012170524A1 (en) 2011-06-06 2012-12-13 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
AU2015255752B2 (en) 2014-05-08 2020-07-23 Immunoforge Co., Ltd. Methods and compositions for treating Cystic Fibrosis
JP6824888B2 (ja) 2015-02-09 2021-02-03 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 筋肉の疾患および障害を治療するための方法および組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62246595A (ja) * 1986-04-17 1987-10-27 Eisai Co Ltd 気菅支拡張作用・降圧作用ペプタイド
US4939224A (en) * 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
SE8705139D0 (sv) * 1987-12-23 1987-12-23 Trion Forskning & Utveckling Forfarande for framstellning av ett stort antal peptidanaloger och nya peptidanaloger
US5141924A (en) * 1989-06-30 1992-08-25 Hoffmann-La Roche, Inc. Synthetic vasoactive intestinal peptide analogs
JPH0692991A (ja) * 1991-02-28 1994-04-05 Daicel Chem Ind Ltd 新規活性ペプチド
US5623050A (en) * 1991-08-22 1997-04-22 Takeda Chemical Industries, Ltd. Stable polypeptides having c-AMP production enhancing activity and the use thereof
JPH06220090A (ja) * 1993-01-22 1994-08-09 Sanwa Kagaku Kenkyusho Co Ltd ポリペプチド
AU682638B2 (en) * 1995-06-09 1997-10-09 ILS, Inc. Peptide, bronchodilator and blood flow ameliorant
JPH11100399A (ja) * 1997-09-26 1999-04-13 Itoham Foods Inc 新規ペプチド誘導体およびそれを有効成分とする薬剤
US6242563B1 (en) * 1998-07-20 2001-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Peptide analogues
JP2001226284A (ja) * 2000-02-18 2001-08-21 Itoham Foods Inc 神経突起誘発剤
JP2003073301A (ja) * 2001-06-22 2003-03-12 Itoham Foods Inc 神経毒性低下剤
EP1462112B1 (de) * 2001-11-06 2009-03-18 Senju Pharmaceutical Co., Ltd. Mittel zur behandlung von augentrockenheit und damit zusammenhängenden erkrankungen
CN1606451A (zh) * 2001-12-19 2005-04-13 伊藤火腿株式会社 构象病的治疗剂和/或预防剂

Also Published As

Publication number Publication date
CN100381462C (zh) 2008-04-16
EP1571155A1 (de) 2005-09-07
JP4477506B2 (ja) 2010-06-09
EP1571155A4 (de) 2005-12-28
WO2004048401A1 (ja) 2004-06-10
US7332473B2 (en) 2008-02-19
EP1571155B1 (de) 2011-08-24
US20060276384A1 (en) 2006-12-07
KR20050067439A (ko) 2005-07-01
JPWO2004048401A1 (ja) 2006-03-23
CN1732182A (zh) 2006-02-08
AU2003284428A1 (en) 2004-06-18
CA2507616A1 (en) 2004-06-10
ES2368565T3 (es) 2011-11-18
AU2003284428B2 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
ATE521624T1 (de) Peptide und medizinische zusammensetzungen mit denselben
ATE330595T1 (de) Formulierung von aminosäuren und riboflavin zur verringerung der toxischen effekte der zytotoxischen chemotherapie
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
GEP201706611B (en) Amido compounds and their use as pharmaceuticals
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
DE60228857D1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
HUP0302319A2 (hu) Gyógyszerkészítmények gyógyászati hatóanyagok szájon át történő bejuttatására
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
ATE549353T1 (de) Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
DE602007002553D1 (de) Ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
TW200638927A (en) Bambuterol and integrin inhibitor combination
BRPI0513051A (pt) combinação de inibidores de transcriptase reversa e de protease anti-hiv
ATE353231T1 (de) Pharmazeutische zusammensetzungen
HK1107699A1 (en) Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound
DE60036199D1 (de) Proteaseresistente flint-analoge
SE0203817D0 (sv) New composition
CO2020001742A2 (es) Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil
EP1730174A4 (de) Peptidträger für die verabreichung von arzneimitteln
DE602004017062D1 (de) Zusammensetzungen aus deramciclan und opioiden zur verwendung als schmerzmittel
BR0215498A (pt) Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties